As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...

Amgen is one of the world’s largest biotechnology ... which closed at $54.92 on Oct. 14. Gilead Sciences is a biopharmaceutical company that develops treatments for HIV/AIDS, hepatitis C ...

Bernstein said Thursday it has started research coverage of US biopharma stocks, voicing a positive outlook for the sector.

Amgen today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of adults with ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

The firm has issued Outperform ratings for Eli Lilly and Company (NYSE:LLY), Gilead Sciences (NASDAQ:GILD), and Amgen (NASDAQ:AMGN). Analysts note that Gilead's rating is supported by the ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...